Abstract | BACKGROUND: METHODS: Seventy-six patients with Hb levels <9.0 g/dl who were scheduled to undergo surgical treatment were randomized to receive either intravenous iron sucrose (based on the calculated total iron deficit divided into 2 ampoule infusions intravenously 3 times a week, beginning 3 weeks before surgery) or oral iron (80 mg/day of oral iron protein succinylate daily). RESULTS: The intravenous iron group had higher increases in Hb (3.0 vs. 0.8 g/dl; p < 0.0001) and ferritin levels (170.1 vs. 4.1 microg/l; p < 0.0001) than the oral iron group. Achieving the target Hb was also higher in the intravenous iron group than in the oral iron group (76.7 vs. 11.5%; p < 0.0001). There were tolerable adverse events in both groups. CONCLUSION:
|
Authors | Yun Hwan Kim, Hyun Hoon Chung, Soon-Beom Kang, Seung Cheol Kim, Young Tae Kim |
Journal | Acta haematologica
(Acta Haematol)
Vol. 121
Issue 1
Pg. 37-41
( 2009)
ISSN: 1421-9662 [Electronic] Switzerland |
PMID | 19332985
(Publication Type: Clinical Trial, Phase IV, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | (c) 2009 S. Karger AG, Basel. |
Chemical References |
- Ferric Compounds
- Hematinics
- Hemoglobins
- Ferritins
- Ferric Oxide, Saccharated
- Glucaric Acid
|
Topics |
- Administration, Oral
- Adult
- Anemia
(blood, therapy)
- Female
- Ferric Compounds
(administration & dosage)
- Ferric Oxide, Saccharated
- Ferritins
(blood)
- Glucaric Acid
- Hematinics
(administration & dosage)
- Hemoglobins
(analysis)
- Humans
- Infusions, Intravenous
- Menorrhagia
(blood, therapy)
- Middle Aged
- Preoperative Care
- Prospective Studies
|